Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 3/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.39 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.39 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | ICMT | O60725 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4799311 | 0.89 | FSCN1 (0.39) | PPARGHDAC1HDAC6HDAC8HDAC3 | |
| SCHEMBL2943251 | 0.88 | PPARG (0.43) | PPARGHDAC1HDAC6HDAC8HDAC3 | |
| SCHEMBL2945087 | 0.87 | PPARG (0.42) | PPARGHDAC1HDAC6HDAC8HDAC3 | |
| SCHEMBL1684192 | 0.86 | PPARG (0.41) | PPARGHDAC1HDAC6HDAC8HDAC3 | |
| SCHEMBL2943245 | 0.84 | FSCN1 (0.42) | PPARGHDAC1HDAC6HDAC8HDAC3 | |
| SCHEMBL2949469 | 0.84 | FSCN1 (0.42) | PPARGHDAC1HDAC6HDAC8HDAC3 | |
| SCHEMBL2945177 | 0.84 | HDAC1 (0.41) | PPARGHDAC1HDAC6HDAC8HDAC3 | |
| SCHEMBL2944846 | 0.83 | PPARG (0.40) | ALDH1A1PPARGHDAC1HDAC6HDAC8 | |
| SCHEMBL2944845 | 0.83 | PPARG (0.40) | ALDH1A1PPARGHDAC1HDAC6HDAC8 | |
| SCHEMBL1684175 | 0.83 | HDAC1 (0.38) | PPARGHDAC1HDAC6HDAC8HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7468375-B2 | Inhibitors of the HIV integrase enzyme | PFIZER INC. (US) | 2008-12-23 | — | — | US | claimed |
| US-20050277662-A1 | Inhibitors of the HIV integrase enzyme | AGOURON PHARMACEUTICALS, INC | 2005-12-15 | — | — | US | claimed |
| US-7468375-B2 | Inhibitors of the HIV integrase enzyme | PFIZER INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7468375-B2 | Inhibitors of the HIV integrase enzyme | PFIZER INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7468375-B2 | Inhibitors of the HIV integrase enzyme | PFIZER INC. (US) | 2008-12-23 | — | — | US | disclosed |
| WO-2008063114-A9 | AMINO- IMIDAZOLONES AND THEIR USE AS MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | WO | disclosed |
| US-20050277662-A1 | Inhibitors of the HIV integrase enzyme | AGOURON PHARMACEUTICALS, INC | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277662-A1 | Inhibitors of the HIV integrase enzyme | IMPDH1, INTS9, TYMP | ALDH1A1 437/4885PPARG 4290/4885HDAC1 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.